August 20, 2021
Article
The investigators concluded that a definite statement on risk or management recommendations cannot be made based on currently published data.
June 10, 2021
Risankizumab-rzaa (Skyrizi, AbbVie) is approved for the treatment of moderate-to-severe plaque psoriasis among adults who are candidates for systemic therapy or phototherapy.
June 07, 2021
Guselkumab also showed promising results in the treatment of psoriatic arthritis, with improved disease activity in joints and across multiple domains through 1 year.
June 03, 2021
This is the first approval for secukinumab in a pediatric population in the United States for severe plaque psoriasis.
April 23, 2021
The POETYK PSO-1 and POETYK PSO-2 trials, which evaluated deucravacitinib 6 mg once daily, met both co-primary endpoints versus placebo, with significantly more patients achieving Psoriasis Area and Severity Index (PASI) 75 response and a static Physician's Global Assessment score of clear or almost clear (sPGA 0/1) after 16 weeks of treatment with deucravacitinib.
April 06, 2021
Some drugs commonly used for psoriasis can increase the risk of cardiovascular diseases, whereas other treatments can reduce the risk.
January 08, 2021
According to the study authors, this could lead to finding the exact molecular trigger and gives hope for developing a targeted PsA treatment in the future.
October 01, 2020
The FDA has approved golimumab for the treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis.
June 28, 2020
A virtual symposium held in conjunction with the Asembia Specialty Pharmacy Summit focused on psoriatic arthritis.
January 09, 2020
Secukinumab provided early and sustained resolution of enthesitis in patients with psoriatic arthritis based on post hoc analysis pooled data from the FUTURE trial.
